IndieBio

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Solving gout using engineered probiotics

Solving gout using engineered probiotics

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases, particularly hyperkalemia, which involves high potassium levels. The company operates a wearable platform that delivers accurate and real-time potassium measurements through interstitial fluid from the skin, providing data closely correlated to blood levels. This innovation is crucial for heart and kidney care, as it enables clinicians and patients to monitor potassium levels effectively. By facilitating timely and informed decision-making regarding medications, diet, and treatment options, Proton Intelligence aims to enhance health outcomes and improve the quality of life for individuals living with chronic conditions.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Allied Microbiota, LLC is a biotechnology company focused on developing microbial products and enzymes to address environmental contamination more efficiently and cost-effectively than traditional remediation methods. Originating from technology at Columbia University, the company's flagship product, PacBac, offers a microbial-based solution for the rapid reduction of stubborn soil contaminants, including poly-chlorinated biphenyls (PCBs), achieving up to 80% reduction in just days. This innovative approach presents significant cost savings—up to 80% compared to conventional remediation techniques like incineration—while effectively eliminating contaminants as a liability rather than merely relocating them. In addition to PacBac, Allied Microbiota is engaged in ongoing research and development to identify new microbial strains and create additional bio-products using advanced methodologies in synthetic biology, proteomics, and data science. By focusing on sustainable biochemicals and biological remediation methods, the company aims to transform the soil-remediation industry, which is valued at approximately $20 billion annually.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Synthetix is a decentralized synthetic asset issuance protocol operating on the Ethereum blockchain, designed for derivatives trading within the decentralized finance (DeFi) space. Based in Sydney, Australia, the platform enables the creation of on-chain synthetic assets and digital tokens. Synthetix offers various products, including the Synthetix Network Token (SNX), which serves as collateral for synthetic assets like sUSD and sEUR. Additionally, it provides Mintr, a decentralized application for SNX holders, and Swappr, a tool facilitating conversions between SNX and Ethereum. The platform aims to address the challenges of volatility in cryptocurrencies by allowing users to gain exposure to real-world currencies, commodities, and indices through synthetic assets, thereby ensuring liquidity and enabling peer-to-contract trading. Founded in 2018, Synthetix promotes an open and transparent ecosystem, leveraging smart contracts to enhance trading efficiency and accessibility.

Liberum Biotech is a biotechnology company focused on advancing protein manufacturing through proprietary molecular and hardware technologies. Its platform facilitates the rapid production of enzymes, therapeutics, and laboratory reagents, enabling clients to enhance speed and scalability while significantly reducing costs. By leveraging its innovative protein synthesizers, Liberum aims to democratize access to synthetic biology, ultimately transforming existing biologics manufacturing practices and making these technologies more accessible to a broader range of users.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Convalesce Inc. is a therapeutic company focused on developing stem cell-based therapies for neurodegenerative conditions, including Parkinson's disease. Founded in 2018 and headquartered in San Francisco, California, the company utilizes advanced biomaterials to enhance its treatment approaches. Convalesce aims to address the degeneration of neurons associated with various neurological disorders through innovative therapeutic solutions.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.

Beeline Therapeutics is an early-stage preclinical cell therapy company focused on developing advanced immune cell therapies for immune-mediated diseases, where the body's immune system mistakenly attacks healthy tissue. The company specializes in genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo, aiming to induce tolerance. Specifically, Beeline re-engineers Regulatory T cells (Tregs) to enhance their function by producing optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins. By combining these enhanced Treg capabilities with antigen specificity through targeted receptors, Beeline seeks to improve the localization of therapies, thereby advancing the development of new cell therapies for various immune-mediated conditions.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Guided Clarity, Inc. develops and manufactures bioactive peptides, which target mitochondrial health for the aging population. The company’s products include medical food that isolates individual bioactive proteins with mitochondrial renewing properties. Guided Clarity, Inc. was founded in 2018 and is based in San Francisco, California.

11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Convalesce Inc. is a therapeutic company focused on developing stem cell-based therapies for neurodegenerative conditions, including Parkinson's disease. Founded in 2018 and headquartered in San Francisco, California, the company utilizes advanced biomaterials to enhance its treatment approaches. Convalesce aims to address the degeneration of neurons associated with various neurological disorders through innovative therapeutic solutions.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Vetherapy is a biotechnology company based in San Francisco, California, specializing in veterinary regenerative medicine and tissue engineering. Founded in 2015, the company develops stem cell therapy products for cats, dogs, and horses, aimed at accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy emphasizes quality and safety in its processes, which include the isolation, expansion, and cryopreservation of stem cells, as well as the preparation of platelet-rich plasma. By providing veterinarians with access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these therapeutic products are readily available for immediate use, addressing various clinical needs for animal patients.

Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.

MezoMax, Inc. is a biotechnology company established in 2017 and headquartered in San Francisco, California. The company specializes in oral therapies designed to repair nonhealing fractures and promote strong bones. MezoMax's innovative approach includes a novel calcium gluconate stereoisomer that enhances the healing of bone fractures, improves osteoporosis treatment, and supports overall bone health, particularly in elderly patients. By focusing on the restoration of bone tissue and the treatment of various bone diseases, MezoMax aims to address significant challenges in bone health and recovery.

Nivien Therapeutics is a Boston-based company founded in 2016 that focuses on developing innovative treatments for patients suffering from resistant cancers. The company has pioneered the creation of the first small molecule inhibitors of the Hippo signaling pathway, which are designed to enhance both chemotherapy and immunotherapy. Nivien Therapeutics is committed to advancing its unique platform that improves the efficacy of immuno-oncology and chemotherapy combinations, particularly for patients who do not respond to conventional treatments. By collaborating with top research institutes, the company aims to de-risk the transfer of technology assets and build a robust portfolio of biotechnology investments.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

NEUROCARRUS INC, a biotechnology company, develops a novel drug delivery technology to disrupt pain signals without addiction-forming medications or disruption of muscular control. The company was incorporated in 2017 and is headquartered in Lincoln, Nebraska.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for diseases that have significant unmet medical needs. Established in 2014 and headquartered in Toronto, Canada, the company specializes in the manufacture of small molecule drugs aimed at complex targets associated with challenging diseases. Proteorex utilizes a proprietary drug discovery platform that combines innovative synthesis design, computational modeling, and patient-derived cell-based screening to identify new small molecule lead compounds. This approach enables the rapid and cost-effective exploration of druggable genomic targets that have been previously deemed undruggable by conventional methodologies. Additionally, Proteorex has an office in San Francisco to support its research and development efforts.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Stelvio Oncology, founded in 2017 and based in San Francisco, California, specializes in developing therapeutics for glioblastoma, an aggressive form of brain cancer. The company focuses on converting glioblastoma multiforme tumor cells into healthy cells by leveraging unique epigenetic signatures associated with specific cell types. Stelvio employs advanced technologies, including microscopic imaging of epigenetic landscapes, to identify small molecules that can induce differentiation or reverse cancerous cells into benign states. This personalized approach aims to provide innovative treatment options for glioblastoma patients, combining scientific creativity with clinical expertise to advance drug therapies and precision medicine diagnostics.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

VenomYx, Inc. is a company based in San Diego, California, that specializes in the development and marketing of snake antivenom for treating snakebite victims. Established in 2015, VenomYx is pioneering the production of toxin-specific snake antivenom, aiming to modernize antivenom treatment. The company's innovative approach seeks to provide safe, effective, and affordable solutions for the millions of individuals affected by snakebites globally, addressing a significant gap in the current treatment landscape for this underserved population.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, established in 2016, that specializes in developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company employs a unique therapeutic design methodology that focuses on inhibiting protein-protein interactions and utilizes bioinformatics techniques specifically for gram-negative bacterial species. A2A Pharmaceuticals integrates computational tools and interdisciplinary approaches in its drug development process, leveraging its proprietary SCULPT™ platform to systematically design therapeutic candidates based on experimentally determined target characteristics. In addition to its research and development efforts, the company also offers consulting services to support advancements in the pharmaceutical field.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, established in 2016, that specializes in developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company employs a unique therapeutic design methodology that focuses on inhibiting protein-protein interactions and utilizes bioinformatics techniques specifically for gram-negative bacterial species. A2A Pharmaceuticals integrates computational tools and interdisciplinary approaches in its drug development process, leveraging its proprietary SCULPT™ platform to systematically design therapeutic candidates based on experimentally determined target characteristics. In addition to its research and development efforts, the company also offers consulting services to support advancements in the pharmaceutical field.

VenomYx, Inc. is a company based in San Diego, California, that specializes in the development and marketing of snake antivenom for treating snakebite victims. Established in 2015, VenomYx is pioneering the production of toxin-specific snake antivenom, aiming to modernize antivenom treatment. The company's innovative approach seeks to provide safe, effective, and affordable solutions for the millions of individuals affected by snakebites globally, addressing a significant gap in the current treatment landscape for this underserved population.

NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.

Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.